Introduction {#s0005}
============

Autoimmune hepatitis (AIH) is characterized by an autoimmune reaction towards hepatocytes.[@bb0005] The nature of AIH is complex and may depend on interactions between genetic susceptibility and environmental triggers.[@bb0010] Understanding the exact mechanisms involved in AIH development remains elusive. There is considerable evidence supporting a strong association of type 1 AIH with human leukocyte antigen (HLA) (Table S1). In particular, the HLA DRB1\*04:05-DQB1\*04:01 haplotype is related to type 1 AIH in the Japanese.[@bb0015] In northern Europe and North America, the DRB1\*03:01-DQB1\*02:01 and DRB1\*04:01-DQB1\*03:01 haplotypes are seen at an increased frequency in patients with AIH, while DRB1\*15:01-DQB1\*06:02 is observed at a lower frequency.[@bb0020] In Latin Americans, DRB1\*13:01-DQB1\*06:03 correlates significantly with the disease.[@bb0025]

Natural killer (NK) cells play crucial roles in the innate immune response to viruses, bacteria, and tumor cells.[@bb0030] NK cell-mediated responses have also been implicated in the pathogenesis of AIH and other autoimmune diseases.[@bb0035], [@bb0040], [@bb0045] NK cells express a wide array of inhibitory and activating killer cell immunoglobulin-like receptors (KIRs) that detect the expression levels of MHC class I ligands on normal and diseased cells in humans.[@bb0050] The inhibitory signals that are transduced from KIR binding to MHC class I molecules allow NK cells to acquire their full cytotoxic potential.[@bb0055] KIR2DL1 recognizes HLA-C group 2 (HLA-C2) allotypes that share lysine at position 80, while KIR2DL2 and KIR2DL3 are specific for HLA-C group 1 (HLA-C1) allotypes that have asparagine at position 80.[@bb0060] KIR3DL1 binds with high affinity to HLA-B Bw4 molecules containing isoleucine at position 80 (Bw4-80Ile) compared with Bw4 molecules containing threonine at that position (Bw4-80Thr).[@bb0065] KIR3DL2 interacts with HLA-A3 and -A11.[@bb0070]^,^[@bb0075] Although KIR gene complexes are important regulators of innate and adaptive immune responses as well as pathogenetic factors in several autoimmune diseases, there remain few reports on KIRs in AIH susceptibility[@bb0080]^,^[@bb0085] and none addressing disease progression. We therefore sought to determine whether KIR genes, HLA class I molecules, and KIR/HLA pairs were associated with AIH susceptibility or disease progression in a Japanese population.

Patients and methods {#s0010}
====================

Patients {#s0015}
--------

Between January 1979 and June 2018, a total of 255 Japanese patients were diagnosed as having type 1 AIH at Shinshu University Hospital or its affiliated institutions. Among them, 101 patients were excluded for the following reasons: (1) no stored DNA samples (n = 76); (2) other chronic liver disease, such as hepatitis B, hepatitis C, or non-alcoholic steatohepatitis (n = 5); (3) incomplete medical records (n = 8); (4) follow-up ≪6 months (n = 2); and (5) AIH-primary biliary cholangitis overlap syndrome (n = 10). The remaining 154 patients with type 1 AIH were retrospectively included in this study along with 201 volunteer healthy blood donors.[@bb0090] The diagnosis of type 1 AIH was made according to the scoring system of the International Autoimmune Hepatitis Group (IAIHG) revised criteria.[@bb0095] Anti-nuclear antibody and anti-smooth muscle antibody were determined as reported previously.[@bb0100] The antibody titers to soluble liver antigen (SLA) were determined using ELISA kits (QUANTA Lite® Inova Diagnostics, San Diego, CA), whereby a titer of ≥25 U was interpreted as a positive finding according to the manufacturer's protocol and instructions for all assays. Cirrhosis was diagnosed by histological examination and/or imaging studies. Hepatocellular carcinoma was diagnosed by imaging studies, and liver decompensation was identified by bleeding from esophageal varices, ascites, and hepatic encephalopathy. Each patient was initially treated with prednisolone at an oral dosage of 20--50 mg/day that was gradually reduced and then maintained at 5--10 mg/day as reported previously.[@bb0105] Azathioprine at a dose of 50 mg/day was added for only 3 patients whose alanine aminotransferase (ALT) level did not normalize or in whom severe adverse effects were seen from prednisolone therapy, since it and other immunomodulatory drugs were not covered by national health insurance in Japan. Complete biochemical remission was defined as the normalization of aminotransferases and IgG levels.[@bb0110] If patients exhibited an increase in ALT ≫3 times the upper limit of normal as defined as a biochemical relapse, prednisolone therapy was reinstituted.[@bb0115] All individuals were negative for hepatitis B surface antigen, antibodies to hepatitis B core antigen, hepatitis C virus, and the human immunodeficiency virus. No patient had a history of excess alcohol consumption. This study was reviewed and approved by the Institutional Review Board of Shinshu University School of Medicine in Matsumoto, Japan (approval number: 524). Written informed consent was obtained from all participating patients. The investigation was conducted according to the principals of the Declaration of Helsinki.

HLA and KIR genotyping {#s0020}
----------------------

Genomic DNA from all participants was extracted from whole-blood samples using QuickGene-800 assays (Fujifilm, Tokyo, Japan). We genotyped HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 as reported previously.[@bb0120] HLA-A3 and -A11, HLA-Bw4, HLA-B Bw4-80Ile, HLA-B Bw4-80Thr, HLA-C1, and HLA-C2 KIR ligands were assigned based on the amino acid residues of the HLA-A, HLA-B, and HLA-C alleles, as described previously.[@bb0125]^,^[@bb0130] KIR genotyping was performed using PCR with sequence-specific primers.[@bb0135] HLA typing was combined with KIR typing to stratify patients according to predicted KIR-ligand interactions and binding affinities. The selected KIR-HLA pairs were KIR2DL1/2DS1-HLA-C2, 2DL2/2DS2-HLA-C1, 3DL1/3DS1-HLA-Bw4, and 3DL2-HLA-A3 and -A11.

Statistical analysis {#s0025}
--------------------

Categorical variables were compared by Pearson's chi-squared test or Fisher's exact test, as appropriate, and continuous variables were compared using the Mann-Whitney *U* test. Optimal cut-off values were determined by the Youden index. Clinical outcomes as of December 2018 were recorded as liver-related death. Genetic power was calculated using the EZR program of R commander software.[@bb0140] Logistic regression analysis was performed to evaluate associations between HLA-DRB1\*04:05 and KIR3DL1/HLA-B Bw4-80Ile in patients with AIH compared to healthy individuals. The Kaplan-Meier method and log-rank test were used to estimate progression to liver decompensation and survival rates of patients. Multivariate analysis was performed using the Cox proportional hazards model with stepwise method to identify independent factors associated with progression to liver decompensation and liver-related death. Variables with a *p* ≪0.1 in univariate analysis were included in this step. A *p* value of ≪0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics version 24 software (IBM, Chicago, IL).

Results {#s0030}
=======

Baseline clinical characteristics of patients {#s0035}
---------------------------------------------

The clinical profile of the experimental patient cohort is shown in [Table 1](#t0005){ref-type="table"}. Median age was 59 years and 88% were female. Median follow-up was 11.1 years (interquartile range: 6.4--17.3 years). According to the IAIHG revised scoring system, 135 and 19 patients fulfilled the criteria for definite and probable AIH, respectively. No patient was positive for anti-SLA in our cohort. At diagnosis, liver biopsy was performed in 152 of 154 patients. One hundred and thirty-eight patients (90%) had chronic hepatitis and 16 patients (10%) had cirrhosis; 14 were diagnosed by liver histology and 2 were identified by liver imaging. Prednisolone was administered to all patients and 97% achieved a complete biochemical response. Prednisolone therapy was reinstituted for 64 patients (42%) who relapsed.Table 1Demographic and clinical characteristics of 154 patients with type 1 AIH.Table 1CharacteristicTotal\
(n = 154)Age at diagnosis (years)59 (48-66)Female, n (%)135 (88)Follow-up (years)11.1 (6.4-17.3)AIH score18 (17-19)Definite AIH, n (%)135 (88)AST (U/L)409 (148-818)ALT (U/L)405 (161-948)Total bilirubin (mg/dl)1.7 (0.9-6.5)IgG (mg/dl)2,714 (2,051-3,497)Platelets (×10^4^/μl)17.4 (15.7-18.7)Prothrombin %78.7 (60.0-96.6)ANA, n (%)150 (97)SMA, n (%) (n = 122)66 (54)SLA, n (%)0 (0)Cirrhosis, n (%)16 (10)Complete remission, n (%)149 (97)Relapse, n (%)64 (42)[^1]

Distribution of HLA, KIR, and KIR/HLA in patients with type 1 AIH and controls {#s0040}
------------------------------------------------------------------------------

We determined the KIR ligands (HLA-A3 and -A11, HLA-Bw4, HLA-C1, and HLA-C2) of 154 patients with type 1 AIH and 201 controls (Table S2). The frequency of HLA-B Bw4 was identical between AIH and controls (77%). The frequency of HLA-B Bw4-80Ile was significantly higher in patients with AIH (69%) than in controls (55%) (odds ratio \[OR\] 1.83; 95% CI 1.18--2.84; *p* = 0.0070), while that of HLA-B Bw4-80Thr was lower (16% *vs.* 28%; OR 0.47; 95% CI 0.27--0.79; *p* = 0.0045). The positivity rate of HLA-C2 was significantly less prevalent in patients with AIH (12%) than in controls (24%) (OR 0.41; 95% CI 0.23--0.74; *p* = 0.0025). There were no significant differences between the groups for the frequencies of HLA-A3 or -A11 or HLA-C1. Further analysis of 14 KIR genes in patients with AIH and controls showed the frequencies of all KIR genes to be comparable (Table S2).

Since KIRs interact with specific HLA class I molecules, we examined KIR/KIR-ligand combinations in AIH and control groups to investigate susceptibility or resistance to the disease ([Table 2](#t0010){ref-type="table"}). The frequency of KIR3DL1/HLA-B Bw4-80Ile in patients with AIH was 64% and significantly higher than the 50% observed in healthy individuals (OR 1.82; 95% CI 1.18--2.80; *p* = 0.0062). In contrast, protective effects were seen for KIR3DL1/HLA-B Bw4-80Thr (15% *vs.* 26%, OR 0.49; 95% CI 0.28--0.84; *p* = 0.0092). Patients with AIH had a significantly lower frequency of KIR2DL1/HLA-C2 compared with controls (12% *vs.* 24%, OR 0.41; 95% CI 0.23--0.74; *p* = 0.0025). There were no remarkable differences in the frequencies of other KIR/HLA pairs between the groups.Table 2KIR/HLA frequencies in type 1 AIH and healthy individuals.Table 2AIH\
(n = 154)Healthy individuals\
(n = 201)OR (95% CI)*p* valueKIR2DL1/HLA-C218 (12%)49 (24%)0.41 (0.23-0.74)0.0025KIR2DL2/HLA-C124 (16%)28 (14%)0.662KIR2DS1/HLA-C27 (5%)19 (9%)0.079KIR2DS2/HLA-C126 (17%)32 (16%)0.808KIR3DL1/HLA-B Bw4111 (72%)146 (73%)0.907KIR3DL1/HLA-B Bw4-80Ile99 (64%)100 (50%)1.82 (1.18-2.80)0.0062KIR3DL1/HLA-B Bw4-80Thr23 (15%)53 (26%)0.49 (0.28-0.84)0.0092KIR3DS1/HLA-Bw450 (33%)70 (35%)0.642KIR3DL2/HLA-A3, -A1138 (25%)48 (24%)0.862[^2]

The frequency of the HLA-DRB1\*04:05-DQB1:04:01 haplotype was significantly higher in patients with AIH (69%) than in healthy individuals (28%) (OR 5.62; 95% CI 3.52--8.97; *p* ≪0.001) as in previous studies (Table S2).[@bb0145] Next, we evaluated this haplotype and the KIR3DL1/HLA-B Bw4-80Ile found in association with AIH for independence by logistic regression analysis. Both the HLA-DRB1\*04:05-DQB1:04:01 haplotype (OR 5.67; 95% CI 3.53--9.11; *p* ≪0.001) and KIR3DL1/HLA-B Bw4-80Ile (OR 1.86; 95% CI 1.17--2.98; *p* = 0.009) were independent susceptibility genes related to AIH. AIH susceptibility correlated positively with the combination of the HLA-DRB1\*04:05-DQB1:04:01 haplotype and KIR3DL1/HLA-B Bw4-80Ile (59 of 154 \[38%\] *vs.* 20 of 201 \[10%\]; OR 5.32; 95% CI 3.20--9.89; *p* ≪0.001). We therefore tested for synergic effects between the genetic factors as reported previously.[@bb0150] Based on logistic regression analysis, this method evaluated whether the observed ORs of the 2 independent factors were greater combined than separately. No synergy was observed between the 2 factors in the AIH group (synergy factor = 1.10; 95% CI 0.42--2.85; *P*~synergy~ = 0.852), which confirmed their independence from each other.

Prediction and risk factors associated with liver decompensation and liver-related death {#s0045}
----------------------------------------------------------------------------------------

As shown in [Table 3](#t0015){ref-type="table"}, 19 patients experienced liver decompensation (7 with ascites, 6 with hepatocellular carcinoma, 3 with hepatic encephalopathy, and 3 with bleeding esophageal varices) during a median follow-up period of 10.5 (interquartile range: 6.4--16.7) years. Serum ALT levels (222 *vs.* 428 U/L, *p =* 0.021), platelet count (15.5 *vs.* 17.4x10^4^/μl, *p =* 0.002), and prothrombin time (PT) % (46.9 *vs.* 83.8%, *p ≪*0.001) were all significantly lower in patients who developed liver decompensation than in those who did not. The presence of cirrhosis at diagnosis was also significantly associated with future liver decompensation (47 *vs.* 5%, *p ≪*0.001).Table 3Demographic and clinical characteristics of patients with type 1 AIH.Table 3CharacteristicLiver decompensation\
(n = 19)Liver compensation\
(n = 135)*p* valueDeath\
(n = 13)Survival\
(n = 141)*p* valueAge (years)63 (54-72)59 (48*-*66)0.24163 (55-70)59 (48*-*66)0.198Female, n (%)18 (95)117 (87)0.52913 (100)122 (87)0.331Follow*-*up (years)6.3 (0.9*-*16.3)10.5 (6.6*-*16.8)0.14619.1 (4.7*-*25.0)10.5 (6.5*-*16.8)0.326AIH score18 (17*-*19)18 (17*-*19)0.68619 (17*-*19)18 (17*-*19)0.353Definite AIH, n (%)17 (90)118 (87)0.90811 (85)124 (88)0.927AST (U/L)376 (78*-*594)410 (149*-*835)0.235428 (65*-*595)408 (149*-*834)0.387ALT (U/L)222 (95*-*591)428 (177*-*997)0.021222 (41*-*528)423 (174*-*983)0.049Total bilirubin (mg/dl)3.5 (1.4*-*10.3)1.6 (0.9*-*6.5)0.0543.5 (1.3*-*10.9)1.6 (0.9*-*6.4)0.194IgG (mg/dl)2,981 (2,040*-*4,306)2,692 (2,053*-*3,464)0.4012,981 (1,950*-*4,121)2,698 (2,060*-*3,465)0.609Platelets (×10^4^/μl)15.5 (10.6*-*17.5)17.4 (16.3*-*20.3)0.00215.5 (11.0*-*17.5)17.5 (16.3*-*19.9)0.020Prothrombin %46.9 (41.0*-*75.2)83.8 (67.3*-*98.0)≪0.00146.0 (36.5*-*75.0)80.6 (65.0*-*98.0)0.001ANA, n (%)18 (95)132 (98)0.99213 (100)137 (97)0.767SMA, n (%)8/12 (67)58/110 (53)0.3586/9 (67)60/113 (53)0.661SLA, n (%)0 (0)0 (0)-0 (0)0 (0)--Cirrhosis, n (%)9 (47)7 (5)≪0.0016 (46)10 (7)≪0.001Complete remission, n (%)18 (95)131 (97)0.87212 (92)137 (97)0.899Relapse, n (%)11 (58)53 (39)0.1239 (69)55 (39)0.068[^3]

When HLA, KIR, and KIR/HLA were compared between patients with and without liver decompensation, the frequencies of HLA-B Bw4 (53 *vs.* 80%; OR 0.28; 95% CI 0.10--0.74; *p* = 0.008) and HLA-B Bw4-80Ile (42 *vs.* 73%; OR 0.25; 95% CI 0.08--0.80; *p* = 0.007) were significantly lower in patients with liver decompensation (Table S3). Although no KIRs were notably associated with liver decompensation development (Table S3), KIR3DL1/HLA-B Bw4 (47 *vs.* 76%; OR 0.29; 95% CI 0.11--0.78; *p* = 0.010) and KIR3DL1/HLA-B Bw4-80Ile (37 *vs.* 68%; OR 0.27; 95% CI 0.10--0.74; *p* = 0.008) were significantly less frequent in patients who experienced decompensation ([Table 4](#t0020){ref-type="table"}).Table 4KIR/HLA frequencies in patients with type 1 AIH with or without liver decompensation.Table 4Liver decompensation\
(n = 19)Liver compensation\
(n = 135)OR (95% CI)*p* valueKIR2DL1/HLA-C23 (15%)15 (11%)0.831[\*](#tf0005){ref-type="table-fn"}KIR2DL2/HLA-C11 (5%)23 (17%)0.324[\*](#tf0005){ref-type="table-fn"}KIR2DS1/HLA-C22 (11%)5 (4%)0.454[\*](#tf0005){ref-type="table-fn"}KIR2DS2/HLA-C11 (5%)25 (19%)0.264[\*](#tf0005){ref-type="table-fn"}KIR3DL1/HLA-B Bw49 (47%)102 (76%)0.29 (0.11--0.78)0.010KIR3DL1/HLA-B Bw4-80Ile7 (37%)92 (68%)0.27 (0.10--0.74)0.008KIR3DL1/HLA-B Bw4-80Thr2 (11%)21 (16%)0.816[\*](#tf0005){ref-type="table-fn"}KIR3DS1/HLA-B Bw45 (26%)45 (33%)0.726[\*](#tf0005){ref-type="table-fn"}KIR3DL2/HLA-A3, -A117 (37%)31 (23%)0.303[^4]

Among the 154 patients with AIH, 13 (8%) succumbed to liver-related death (6 from advanced hepatocellular carcinoma and 7 from liver failure) during follow-up. None had received liver transplantation. Those patients had significantly lower median ALT levels (222 *vs.* 423 U/L, *p =* 0.049), platelet count (15.5 *vs.* 17.5 ×10[@bb0020]/μl, *p =* 0.020), and PT % (46.0 *vs.* 80.6%, *p =* 0.001) compared with survivors. Moreover, patients with a poor outcome more frequently had cirrhosis than those with a favorable outcome (46 *vs.* 7%, *p ≪*0.001) ([Table 3](#t0015){ref-type="table"}).

The presence of HLA-B Bw4 (79 *vs.* 46%; OR 0.22; 95% CI 0.07--0.71; *p* = 0.007) and Bw4-80Ile (72 *vs.* 39%; OR 0.25; 95% CI 0.08--0.80; *p* = 0.031) were significantly associated with a favorable outcome (Table S4), with no remarkable associations seen for HLA-A3 or -A11, HLA-C1, or HLA-C2. The frequencies of KIR genes did not differ noticeably between survivors and patients with liver-related death (Table S4). Among KIR/HLA combinations, KIR3DL1/HLA-B Bw4 and KIR3DL1/HLA-B Bw4-80Ile were significantly associated with survival versus liver-related death (75 *vs.* 39%; OR 0.21; 95% CI 0.06--0.67; *p* = 0.012 and 67 *vs.* 31%; OR 0.22; 95% CI 0.06--0.74; *p* = 0.020, respectively) ([Table 5](#t0025){ref-type="table"}).Table 5KIR/HLA frequencies in patients with type 1 AIH according to survival and liver-related death.Table 5Death\
(n = 13)Survival\
(n = 141)OR (95% CI)*p* valueKIR2DL1/HLA-C20 (0%)18 (13%)0.358KIR2DL2/HLA-C11 (8%)23 (16%)0.674KIR2DS1/HLA-C20 (0%)7 (5%)0.899KIR2DS2/HLA-C11 (8%)25 (18%)0.591KIR3DL1/HLA-B Bw45 (39%)106 (75%)0.21 (0.06-0.67)0.012KIR3DL1/HLA-B Bw4-80Ile4 (31%)95 (67%)0.22 (0.06-0.74)0.020KIR3DL1/HLA-B Bw4-80Thr1 (8%)22 (16%)0.720KIR3DS1/HLA-B Bw43 (23%)47 (33%)0.655KIR3DL2/HLA-A3, -A114 (31%)34 (24%)0.844[^5]

According to Cox proportional hazards regression analysis, liver decompensation and liver-related death had significant associations with KIR3DL1/HLA-B Bw4 (hazard ratio \[HR\] 0.37; 95% CI 0.14--0.94; *p =* 0.037 and HR 0.26; 95% CI 0.07--0.93; *p =* 0.038, respectively) and histological evidence of cirrhosis at initial diagnosis (HR 9.00; 95% CI 3.11--26.05; *p ≪*0.001 and HR 17.87; 95% CI 4.61--69.18; *p ≪*0.001, respectively) ([Table 6](#t0030){ref-type="table"}). A PT % of ≫47.5% was a protective factor against liver decompensation (HR 0.21; 95% CI 0.08--0.55; *p =* 0.002), but not against liver-related death.Table 6Factors associated with liver decompensation and liver-related death in AIH.Table 6FactorHR95% CI*p* value**Association with liver decompensation**KIR3DL1/HLA-B Bw4 Positive0.370.14*-*0.940.037 Negative1Cirrhosis Yes9.003.11*-*26.05≪0.001 No1Prothrombin % ≫47.50.210.08*-*0.550.002 ≤47.51**Association with liver*-*related death**KIR3DL1/HLA-B Bw4 Positive0.260.07*-*0.930.038 Negative1Cirrhosis Yes17.874.61*-*69.18≪0.001 No1[^6]

Cumulative incidence of liver decompensation and liver-related death by risk factor {#s0050}
-----------------------------------------------------------------------------------

Kaplan-Meier survival estimates showed that patients with KIR3DL1/HLA-B Bw4 had a significantly lower risk of liver decompensation and liver-related death (log-rank test; *p =* 0.013 and *p =* 0.042, respectively) ([Fig. 1](#f0005){ref-type="fig"}A and [1](#f0005){ref-type="fig"}C). In Kaplan-Meier plots for patients with or without cirrhosis, the cumulative liver decompensation and survival rates between the groups were significantly different (log-rank test; *p ≪*0.001 and *p ≪*0.001, respectively) ([Fig. 1](#f0005){ref-type="fig"}B and [1](#f0005){ref-type="fig"}D). We further divided the patients into 3 groups according to the number of risk factors identified by multivariate analysis (KIR3DL1/HLA-B Bw4-negative and cirrhosis at diagnosis). Patients with both risk factors were assigned to the high-risk group, those with 1 factor to the intermediate-risk group, and those with no factors to the low-risk group. Kaplan-Meier testing showed that the cumulative incidences of liver decompensation and liver-related death were highest in the high-risk group, followed next by the intermediate- and low-risk groups (log-rank test; *p ≪*0.001 and *p ≪*0.001, respectively) ([Fig. 2](#f0010){ref-type="fig"}A and [2](#f0010){ref-type="fig"}B).Fig. 1**Cumulative progression to liver decompensation and survival rates of AIH patients were analyzed using the Kaplan-Meier method.** Progression to liver decompensation was significantly lower in (A) patients with KIR3DL1/HLA-B Bw4 (*p =* 0.043) and higher in (B) those with cirrhosis at diagnosis (*p ≪*0.001). Survival was significantly higher in (C) patients with KIR3DL1/HLA-B Bw4 (*p =* 0.042) and lower in (D) those with cirrhosis at diagnosis (*p ≪*0.001). *p* values were calculated by the log-rank test. AIH, autoimmune hepatitis.Fig. 1Fig. 2**Cumulative progression to liver decompensation and survival according to the number of risk factors of KIR3DL1/HLA-B Bw4 (-) and cirrhosis at diagnosis.** Kaplan-Meier testing showed that the cumulative incidences of (A) liver decompensation and (B) liver-related death were highest in the high-risk group, followed next by the intermediate- and low-risk groups (log-rank test; *p ≪*0.001 and *p ≪*0.001, respectively). Green, red, and blue lines indicate high-risk patients (2 risk factors), intermediate-risk patients (1 risk factor), and low-risk patients (no risk factors), respectively. *p* values were calculated by the log-rank test.Fig. 2

Discussion {#s0055}
==========

The present study examined HLA class I and II alleles, 14 KIR genes, and KIR/HLA combinations in type 1 AIH in a Japanese population. The KIR gene family is highly polymorphic and not well captured by standard genome-wide association study approaches. The key findings were: i) KIR3DL1/HLA-B Bw4-80Ile was significantly associated with the disease and was an independent susceptibility gene along with the HLA-DRB1\*04:05-DQB1\*04:01 haplotype; ii) patients with AIH had significantly lower frequencies of KIR2DL1/HLA-C2 and KIR3DL1/HLA-B Bw4-80Thr, suggesting protection by those KIR-HLA pairs against the disease; iii) KIR3DL1/HLA-B Bw4 and KIR3DL1/HLA-B Bw4-80Ile were protective against liver decompensation and liver-related death; and iv) the absence of KIR3DL1/HLA-B Bw4 and the presence of cirrhosis at diagnosis were strongly related to AIH progression.

This study revealed KIR3DL1/HLA-B Bw4-80Ile to be significantly increased in AIH in addition to the HLA-DRB1\*04:05-DQB1\*04:01 haplotype, a confirmed susceptibility factor in Japan.[@bb0015]^,^[@bb0145] This haplotype has also been associated with primary biliary cholangitis in the Japanese.[@bb0120] Although both genetic factors correlated positively with AIH, we did not observe any synergistic properties. The synergy factor calculations in the present study were designed to be robust for small sample sizes, even when individual cells were zero. The results corroborated the findings that the combination of KIR3DL1/HLA-B Bw4-80Ile and HLA-DRB1\*04:05-DQB1:04:01 haplotypes had no significant advantage over each factor in isolation towards AIH susceptibility, confirming them both as independent disease risk factors.

All HLA-B molecules express 1 of 2 mutually exclusive serological epitopes (Bw4 or Bw6) that are encoded by 5 variable amino acids spanning positions 77--83. Bw6 is exclusive to HLA-B molecules and is present in roughly two-thirds of molecules, while Bw4 is present in the remaining third of HLA-B molecules, as well as in several HLA-A molecules. In this study, Bw4 motifs in HLA-B and HLA-A alleles were further analyzed.[@bb0155]^,^[@bb0160] Receptor-ligand binding and lysis inhibition assays have shown that HLA-B molecules containing Bw4-80Ile may be more effective ligands for KIR3DL1 than those containing Bw4-80Thr.[@bb0065]^,^[@bb0165] This difference might have accounted for the susceptibility observed for KIR3DL1/HLA-B Bw4-80Ile and protection for KIR3DL1/HLA-B Bw4-80Thr in AIH. At present, we can only describe the observation of an inverse effect on AIH development without a sound scientific basis for its occurrence.

Importantly, the present study revealed that the KIR2DL1/HLA-C2 combination, which also has the strongest inhibitory receptor-ligand interaction, was protective against AIH. In Japan, no correlations have been found between KIR2DL1/HLA-C2 and autoimmune diseases. Only a prior study from our group has detected an association of KIR2DL1/HLA-C2 with ulcerative colitis.[@bb0170] Concurrent AIH and inflammatory bowel disease might represent unique entities from either process alone.[@bb0175] Several reports have described that some patients with AIH had ulcerative colitis in addition to features of primary sclerosing cholangitis and younger age of onset.[@bb0180]^,^[@bb0185] In our cohort, however, no case exhibited concurrent inflammatory bowel disease, primary sclerosing cholangitis, or young age of onset, although we could not exclude the possibility that HLA-C2 alone might play a prominent role in AIH resistance since all patients and controls possessed KIR2DL1. The decreased frequency of the strongly inhibitory KIR2DL1/HLA-C2 pair might have been difficult to overcome by simultaneous activation signals to promote autoimmunity in patients with AIH. Previous investigations have revealed that KIR allotypes modulate major NK cell effector function[@bb0190] and KIR3DL1 allotypes modify HLA-B\*57 protection against human immunodeficiency virus-1.[@bb0195] Thus, further studies are required on KIR allotypes to clarify their relationship with AIH.

Interestingly, we observed novel protective effects for KIR3DL1/HLA-B Bw4 and KIR3DL1/HLA-B Bw4-80Ile against progression to liver decompensation and liver-related death in AIH, with KIR3DL1/HLA-B Bw4 remaining an independent predictor of disease progression in multivariate analysis. Several reports have identified that genetic features, in particular HLA DRB1 alleles, influence disease outcome in AIH.[@bb0015]^,^[@bb0200], [@bb0205], [@bb0210] However, none have demonstrated that KIR/HLA combinations influence disease progression and mortality in AIH despite significant associations between KIR/HLA pairs and hepatocellular carcinoma in hepatitis C virus infection.[@bb0135] The precise reasons for this observation are unknown, but the association of this KIR/HLA pair and protection against disease progression is striking.

Kirstein *et al.* reported poor survival in patients with AIH who were anti-SLA positive.[@bb0210] Although none of our patients were positive for anti-SLA antibodies, previous data have suggested an association between SLA antibodies and HLA class II DRB1\*03:01 in Caucasians.[@bb0210] HLA-DRB1\*03:01 was absent in our cohort as its allele frequency is less than 0.15% in the Japanese population.

Lastly, we noticed that patients with cirrhosis at diagnosis had significantly increased risks of liver-related death and liver decompensation in Cox regression and Kaplan-Meier analyses, which was in agreement with studies in Germany and the Netherlands.[@bb0210]^,^[@bb0215]. No significant associations were seen between the frequencies of cirrhosis and KIR3DL1/HLA-B Bw4 by the chi-square test. When the factors of cirrhosis at diagnosis and KIR3DL1/HLA-B Bw4 negativity were combined, patients with both risk factors tended to exhibit a more rapid progression to liver decompensation and liver-related death. In contrast, patients without either risk factor seldom showed liver failure or liver-related death, even at 20 years after diagnosis.

There were several limitations to this study. It was retrospective in nature and contained a small sample size despite its long median follow-up period of 11.1 years. As the numbers of patients who developed liver-related death and liver decompensation were small, further longitudinal multicentric studies including a larger number of cases and controls are required. However, power calculations based on the study of 154 patients with AIH and 201 controls, and an OR of 1.82 at KIR3DL1/HLA-B Bw4, demonstrated sufficient power (0.814) at the 0.05 level of significance.

In conclusion, KIR3DL1/HLA-B Bw4-80Ile, KIR3DL1/HLA-B Bw4-80Thr, and KIR2DL1/HLA-C2 were associated with either AIH susceptibility or protection in a Japanese population. KIR3DL1/HLA-B Bw4 is a novel KIR/HLA pair related to a favorable clinical outcome, while histological cirrhosis at the initial diagnosis is a risk factor for poor prognosis. Thus, frequent and careful surveillance is advised for KIR3DL1/HLA-B Bw4-negative patients with cirrhosis. It should be noted, however, that genetic analysis alone is insufficient to pinpoint the contributions of predisposing KIR-HLA factors; functional clinical and basic studies are also needed to identify the mechanisms by which NK cells protect or predispose individuals to AIH pathogenesis and progression.
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[^1]: Values are expressed as the median (interquartile range) unless otherwise noted. AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; AST, aspartate aminotransferase; SLA, anti-soluble liver antigen; SMA, anti-smooth muscle antibody.

[^2]: AIH, autoimmune hepatitis; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; OR, odds ratio.

[^3]: Values are expressed as the median (interquartile range) unless otherwise noted. AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; SLA, anti-soluble liver antigen; SMA, anti-smooth muscle antibody.

[^4]: Fisher's exact test. AIH, autoimmune hepatitis; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; OR, odds ratio.

[^5]: AIH, autoimmune hepatitis; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; OR, odds ratio.

[^6]: Cox proportional hazard model. AIH, autoimmune hepatitis; HLA, human leukocyte antigen; HR, hazard ratio; KIR, killer cell immunoglobulin-like receptor.
